암 생검 시장 : 제품 유형별, 적응증별 - 세계 전망(2025-2030년)

The Cancer Biopsy Market was valued at USD 29.84 billion in 2023, expected to reach USD 33.48 billion in 2024, and is projected to grow at a CAGR of 12.28%, to USD 67.14 billion by 2030.

The cancer biopsy market encompasses the array of procedures used to extract tissue samples for the diagnosis and monitoring of cancerous growths. Biopsies are crucial as they provide definitive cancer diagnoses, enabling physicians to devise effective treatment strategies. This market includes traditional techniques like needle and surgical biopsies, as well as emerging methods such as liquid biopsies, which analyze biomarkers in bodily fluids. The necessity of biopsies is underscored by the increasing global incidence of cancer and the growing demand for less invasive diagnostic tools. Biopsies find application across multiple end-use segments, including hospitals, diagnostic centers, and research institutes. Key growth drivers for this market include advancements in biopsy technologies, the rising adoption of personalized medicine, and increased healthcare spending. The development of AI-driven imaging and analysis tools presents significant opportunities, streamlining diagnosis and improving accuracy. However, the market faces limitations such as the relatively high cost of advanced biopsy methods, regulatory hurdles, and patient reluctance towards invasive procedures. Challenges also include the scarcity of skilled professionals and technological gaps in low-resource settings. For businesses, innovation in non-invasive biopsy techniques like liquid biopsy can be pivotal, given its potential to detect cancers at an earlier stage. Furthermore, investing in automated biopsy technologies and real-time data analysis systems can enhance market position and contribute to personalized treatment plans. The market is competitive, driven by rapid technological evolution, thus requiring companies to stay ahead with ongoing R&D efforts. It's crucial for businesses to focus on collaborations with research institutes to foster innovation and expand applicability. Overall, by prioritizing accessibility, cost-effectiveness, and technological integration, companies can effectively navigate this evolving market landscape and capitalize on emerging opportunities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Biopsy Market

The Cancer Biopsy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing preference for non-invasive procedures
  • Emerging significance of cancer biopsies and tissue sectioning
  • Growing adoption of liquid cancer biopsies
• Market Restraints
  • Low sensitivity and specificity of cancer biopsies
• Market Opportunities
  • Technological advancements in cancer biopsy devices
  • Increasing R&D activities for novel cancer treatments
• Market Challenges
  • Stringent regulatory requirements and unclear reimbursement scenarios

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Biopsy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Biopsy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Biopsy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Biopsy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Biopsy Market

A detailed market share analysis in the Cancer Biopsy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Biopsy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Biopsy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Biopsy Market

A strategic analysis of the Cancer Biopsy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biopsy Market, highlighting leading vendors and their innovative profiles. These include Agena Bioscience, Inc., Agilent Technologies Inc., ANGLE PLC, Becton, Dickinson and Company, BIOCEPT, Inc., Danaher Corporation, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Freenome Holdings, Inc., GRAIL, Inc., Guardant Health, HelioHealth, Hologic, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, Lucence Health Inc., MDx Health, Myriad Genetics, Inc., Natera, Inc., OncoCyte Corp, Personalis Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., and Trovagene, Inc.

Market Segmentation & Coverage

This research report categorizes the Cancer Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Instruments, Kits & Consumables, and Services.
• Based on Type, market is studied across Liquid Biopsies and Tissue Biopsies. The Tissue Biopsies is further studied across Needle Biopsies and Surgical Biopsies. The Needle Biopsies is further studied across Core Needle Biopsy and Fine Needle Aspiration.
• Based on Indication, market is studied across Blood Cancers, Breast Cancer, Cervical Cancers, Colorectal Cancer, Kidney Cancers, Liver Cancers, Lung Cancers, Ovarian Cancers, Pancreatic Cancers, Prostate Cancers, and Skin Cancers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing preference for non-invasive procedures
    • 5.1.1.2. Emerging significance of cancer biopsies and tissue sectioning
    • 5.1.1.3. Growing adoption of liquid cancer biopsies
  • 5.1.2. Restraints
    • 5.1.2.1. Low sensitivity and specificity of cancer biopsies
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in cancer biopsy devices
    • 5.1.3.2. Increasing R&D activities for novel cancer treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory requirements and unclear reimbursement scenarios
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cancer Biopsy Market, by Product

• 6.1. Introduction
• 6.2. Instruments
• 6.3. Kits & Consumables
• 6.4. Services

7. Cancer Biopsy Market, by Type

• 7.1. Introduction
• 7.2. Liquid Biopsies
• 7.3. Tissue Biopsies
  • 7.3.1. Needle Biopsies
    • 7.3.1.1. Core Needle Biopsy
    • 7.3.1.2. Fine Needle Aspiration
  • 7.3.2. Surgical Biopsies

8. Cancer Biopsy Market, by Indication

• 8.1. Introduction
• 8.2. Blood Cancers
• 8.3. Breast Cancer
• 8.4. Cervical Cancers
• 8.5. Colorectal Cancer
• 8.6. Kidney Cancers
• 8.7. Liver Cancers
• 8.8. Lung Cancers
• 8.9. Ovarian Cancers
• 8.10. Pancreatic Cancers
• 8.11. Prostate Cancers
• 8.12. Skin Cancers

9. Americas Cancer Biopsy Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cancer Biopsy Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Biopsy Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Agena Bioscience, Inc.
• 2. Agilent Technologies Inc.
• 3. ANGLE PLC
• 4. Becton, Dickinson and Company
• 5. BIOCEPT, Inc.
• 6. Danaher Corporation
• 7. Epigenomics AG
• 8. Exact Sciences Corporation
• 9. F. Hoffmann-La Roche Ltd.
• 10. Freenome Holdings, Inc.
• 11. GRAIL, Inc.
• 12. Guardant Health
• 13. HelioHealth
• 14. Hologic, Inc.
• 15. Illumina, Inc.
• 16. Laboratory Corporation of America Holdings
• 17. Lucence Health Inc.
• 18. MDx Health
• 19. Myriad Genetics, Inc.
• 20. Natera, Inc.
• 21. OncoCyte Corp
• 22. Personalis Inc.
• 23. QIAGEN N.V.
• 24. Thermo Fisher Scientific, Inc.
• 25. Trovagene, Inc